Clinical Trial

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Protocol Amendment History 2 changes
notable Trial sites expanded: 254 -> 260 locations 2026-06-24
minor Completion pushed: 2029-05-11 -> 2031-05-11 2026-06-24
Trial Details
NCT Number NCT05555732
Lead Sponsor Daiichi Sankyo
Collaborators: AstraZeneca, Merck Sharp & Dohme LLC
Conditions Metastatic Non Small Cell Lung Cancer
Enrollment 1,170 participants
Start Date 2023-01-11
Primary Completion 2029-05-11 (estimated)
Study Completion 2031-05-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-23